JP6817966B2 - 高アンモニア血症に関連する疾患を治療するために操作された細菌 - Google Patents

高アンモニア血症に関連する疾患を治療するために操作された細菌 Download PDF

Info

Publication number
JP6817966B2
JP6817966B2 JP2017564379A JP2017564379A JP6817966B2 JP 6817966 B2 JP6817966 B2 JP 6817966B2 JP 2017564379 A JP2017564379 A JP 2017564379A JP 2017564379 A JP2017564379 A JP 2017564379A JP 6817966 B2 JP6817966 B2 JP 6817966B2
Authority
JP
Japan
Prior art keywords
arginine
promoter
genetically engineered
gene
bacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017564379A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523978A (ja
JP2018523978A5 (cg-RX-API-DMAC7.html
Inventor
ファルブ ディーン
ファルブ ディーン
エム イザベラ ビンセント
エム イザベラ ビンセント
ダヴリュー コツラ ジョナサン
ダヴリュー コツラ ジョナサン
エフ ミラー ポール
エフ ミラー ポール
マシナーニ スーマン
マシナーニ スーマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synlogic Inc
Original Assignee
Synlogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/960,333 external-priority patent/US9487764B2/en
Priority claimed from PCT/US2016/020530 external-priority patent/WO2016141108A1/en
Application filed by Synlogic Inc filed Critical Synlogic Inc
Publication of JP2018523978A publication Critical patent/JP2018523978A/ja
Publication of JP2018523978A5 publication Critical patent/JP2018523978A5/ja
Application granted granted Critical
Publication of JP6817966B2 publication Critical patent/JP6817966B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/10—Citrulline; Arginine; Ornithine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2017564379A 2015-06-10 2016-05-25 高アンモニア血症に関連する疾患を治療するために操作された細菌 Expired - Fee Related JP6817966B2 (ja)

Applications Claiming Priority (31)

Application Number Priority Date Filing Date Title
US201562173710P 2015-06-10 2015-06-10
US201562173706P 2015-06-10 2015-06-10
US62/173,706 2015-06-10
US62/173,710 2015-06-10
US201562183935P 2015-06-24 2015-06-24
US62/183,935 2015-06-24
US201562184811P 2015-06-25 2015-06-25
US201562184770P 2015-06-25 2015-06-25
US62/184,811 2015-06-25
US62/184,770 2015-06-25
US201562248805P 2015-10-30 2015-10-30
US62/248,805 2015-10-30
US201562256048P 2015-11-16 2015-11-16
US201562256039P 2015-11-16 2015-11-16
US201562256041P 2015-11-16 2015-11-16
US62/256,039 2015-11-16
US62/256,048 2015-11-16
US62/256,041 2015-11-16
US201562263329P 2015-12-04 2015-12-04
US14/960,333 US9487764B2 (en) 2014-12-05 2015-12-04 Bacteria engineered to treat diseases associated with hyperammonemia
US62/263,329 2015-12-04
US14/960,333 2015-12-04
US201662277654P 2016-01-12 2016-01-12
US62/277,654 2016-01-12
US201662291468P 2016-02-04 2016-02-04
US62/291,468 2016-02-04
US201662293749P 2016-02-10 2016-02-10
US62/293,749 2016-02-10
PCT/US2016/020530 WO2016141108A1 (en) 2015-03-02 2016-03-02 Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
USPCT/US2016/020530 2016-03-02
PCT/US2016/034200 WO2016200614A2 (en) 2015-06-10 2016-05-25 Bacteria engineered to treat diseases associated with hyperammonemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020217391A Division JP2021061846A (ja) 2015-06-10 2020-12-25 高アンモニア血症に関連する疾患を治療するために操作された細菌

Publications (3)

Publication Number Publication Date
JP2018523978A JP2018523978A (ja) 2018-08-30
JP2018523978A5 JP2018523978A5 (cg-RX-API-DMAC7.html) 2019-06-20
JP6817966B2 true JP6817966B2 (ja) 2021-01-20

Family

ID=57504262

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017564379A Expired - Fee Related JP6817966B2 (ja) 2015-06-10 2016-05-25 高アンモニア血症に関連する疾患を治療するために操作された細菌
JP2020217391A Pending JP2021061846A (ja) 2015-06-10 2020-12-25 高アンモニア血症に関連する疾患を治療するために操作された細菌

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020217391A Pending JP2021061846A (ja) 2015-06-10 2020-12-25 高アンモニア血症に関連する疾患を治療するために操作された細菌

Country Status (5)

Country Link
EP (1) EP3307879A2 (cg-RX-API-DMAC7.html)
JP (2) JP6817966B2 (cg-RX-API-DMAC7.html)
AU (1) AU2016274311A1 (cg-RX-API-DMAC7.html)
CA (1) CA2988930A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016200614A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136795A1 (en) 2016-02-04 2017-08-10 Synlogic, Inc. Bacteria engineered to treat diseases associated with tryptophan metabolism
KR20200018488A (ko) * 2017-05-24 2020-02-19 토리스 게엠베하 고암모니아혈증을 치료하기 위한 글루타민 합성효소의 용도
MX2020005875A (es) 2017-12-05 2020-10-08 Bioplx Inc Métodos y composiciones para prevenir la infección microbiana.
CN110446259B (zh) * 2018-05-04 2022-04-15 大唐移动通信设备有限公司 一种寻呼机会的位置确定方法及通信设备
KR20220003030A (ko) 2019-04-29 2022-01-07 신로직 오퍼레이팅 컴퍼니, 인코포레이티드 살아 있는 세포 계수 기술에 의한 유전적으로 조작된 미생물의 계수
WO2020239882A1 (en) 2019-05-30 2020-12-03 Recordati Industria Chimica E Farmaceutica S.P.A. Pharmaceutical formulation for carglumic acid
CA3142608A1 (en) 2019-06-04 2020-12-10 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
EP4067476B1 (en) 2019-11-29 2025-08-27 Jinis Co., Ltd. Strain having ability to lower blood ammonia levels and composition comprising same for neuronal protection
EP3839051A1 (en) * 2019-12-19 2021-06-23 Evonik Operations GmbH Method for the fermentative production of guanidinoacetic acid
AU2021393455A1 (en) 2020-12-02 2023-06-29 Synlogic Operating Company, Inc. Engineered microorganisms
WO2022210867A1 (ja) 2021-03-31 2022-10-06 日本製鉄株式会社 無方向性電磁鋼板、無方向性電磁鋼板の打ち抜き方法および無方向性電磁鋼板の打ち抜き用金型
CN119592452B (zh) * 2024-11-23 2025-12-02 清华大学 洋葱伯克霍尔德菌及其浸出废料中稀土元素的方法
CN120000813A (zh) * 2025-02-17 2025-05-16 温州医科大学 工程益生菌在防治阿尔茨海默病中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3083315B2 (ja) * 1990-10-29 2000-09-04 株式会社ヤクルト本社 血中アンモニア低下剤
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
IT1290679B1 (it) * 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
CA2353800A1 (en) 1998-12-02 2000-06-08 Trustees Of Boston University Gene networks for control of gene expression
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
WO2009123029A1 (ja) * 2008-03-31 2009-10-08 株式会社 大塚製薬工場 血中アンモニア調整剤
AU2014331610B2 (en) * 2013-10-03 2019-11-07 Trustees Of The University Of Pennsylvania Compositions comprising a defined microbiome and methods of use thereof

Also Published As

Publication number Publication date
JP2018523978A (ja) 2018-08-30
CA2988930A1 (en) 2016-12-15
JP2021061846A (ja) 2021-04-22
EP3307879A2 (en) 2018-04-18
WO2016200614A2 (en) 2016-12-15
AU2016274311A1 (en) 2018-01-18
WO2016200614A3 (en) 2017-01-12

Similar Documents

Publication Publication Date Title
US11845964B2 (en) Bacteria engineered to treat diseases associated with hyperammonemia
US12409195B2 (en) Bacteria engineered to reduce hyperphenylalaninemia
JP2021061846A (ja) 高アンモニア血症に関連する疾患を治療するために操作された細菌
JP7494345B2 (ja) 高フェニルアラニン血症を低減させるように操作された細菌
US20220233609A1 (en) Bacteria engineered to treat disorders in which oxalate is detrimental
EP3307870B1 (en) Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
JP6768689B2 (ja) 高アンモニア血症に関連する病気を処置するために操作された細菌
BR112017018656B1 (pt) Bactéria geneticamente modificada, composição farmaceuticamente aceitável compreendendo a dita bactéria e uso da dita composição para tratar ou prevenir uma doença ou condição associada à inflamação intestinal e/ou função da barreira intestinal comprometida
US20170216370A1 (en) Bacteria engineered to treat disorders involving propionate catabolism
JP2018535678A5 (cg-RX-API-DMAC7.html)
US20230174926A1 (en) Bacteria engineered to treat disorders involving the catabolism of leucine
US20230090705A1 (en) Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof
JP2018521674A (ja) プロピオネート異化を伴う障害を治療するために操作された細菌
US20220168362A1 (en) Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
JP2018523978A5 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190517

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200629

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201225

R150 Certificate of patent or registration of utility model

Ref document number: 6817966

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees